But a stubborn handful of receptors has resisted every attempt at de-orphanization. TAS2R19, TAS2R42, TAS2R45, and TAS2R60 remain orphans, receptors with no known activating compounds, and their biological roles have therefore remained shrouded in uncertainty. At the same time, even among receptors classified as functional, genetic variation has produced variants labeled nonfunctional, sometimes on the basis of just one or a few amino acid substitutions. Two famous examples are TAS2R9 and TAS2R38. In TAS2R9, an alanine at position 187 yields a functional receptor, while a valine at the same position renders it unresponsive to known agonists such as the antibiotic ofloxacin. TAS2R38 is even more celebrated: its PAV variant makes people exquisitely sensitive to the bitter compounds phenylthiocarbamide and propylthiouracil, whereas the AVI variant is classed as nonfunctional and defines the classic taster-non-taster divide in human populations. Whether such variants are truly dead or have simply shifted their ligand preferences to unknown chemicals has been impossible to determine from sequence alone.

A new study by Praveen Kumar and Maik Behrens, published in Current Research in Food Science, tackles this puzzle from an unexpected angle. Instead of hunting for missing agonists, the researchers asked a more fundamental question: do these orphan and supposedly nonfunctional receptors even reach the cell surface, the location where a receptor must reside to detect compounds outside the cell? A receptor that fails to fold properly, or that gets stuck in the endoplasmic reticulum during biosynthesis, can never respond to any ligand, no matter how thorough the screening. Conversely, a receptor that traffics efficiently to the plasma membrane is structurally intact and remains a plausible candidate for future ligand discovery. The answer to this question provides a powerful clue about functionality that does not require knowing a single agonist.

To measure cell surface localization, the team employed a clever tagging strategy developed recently in their laboratory. Each receptor was engineered to carry an 11-amino-acid HiBiT sequence, a small peptide tag appended to the amino-terminal end of an sst3 export tag derived from the rat somatostatin receptor subtype 3, which is itself crucial for routing receptors to the plasma membrane. The HiBiT tag binds with high affinity to a complementary protein fragment called LgBiT, and together the two fragments generate luminescence. Because some of the commercial detection reagents are membrane-impermeable, they can only reach HiBiT tags exposed on the outside of living cells, allowing researchers to quantify exactly how much of each receptor sits at the cell surface. A second, lytic detection reagent breaks the cells open and reveals the total receptor population, permitting calculation of the fraction that successfully completed trafficking. The entire workflow runs on a fluorometric imaging plate reader, making it suitable for high-throughput analysis.

The first test cases were the taster and non-taster variants of TAS2R9 and TAS2R38. Functional assays in HEK293T-Gα16gust44 cells confirmed the expected behavior: the TAS2R38-PAV variant responded to propylthiouracil and the TAS2R9-187A variant responded to ofloxacin, while their non-taster counterparts remained silent. Importantly, adding the HiBiT tag did not abolish function, although the tagged TAS2R38 showed a slightly reduced response, a caveat the authors note openly. When the researchers then measured cell surface abundance using the luminescence assay, both functional and nonfunctional variants proved to be present at the plasma membrane. The non-taster TAS2R38-AVI variant reached the cell surface at a reduced fraction, about 6 percent of its total pool compared with 17 percent for the PAV variant, and the TAS2R9-187V variant showed only a modest reduction relative to its functional partner. Immunocytochemical staining of living, non-permeabilized cells with an anti-HiBiT antibody independently confirmed these surface-localization patterns.

These results carry significant implications for how scientists interpret receptor polymorphisms. For TAS2R9-187V, the data suggest that no gross defect in folding or routing explains its apparent nonfunctionality. Position 187 sits in the upper part of the fifth transmembrane domain, a region that could plausibly contribute to agonist binding. The authors therefore propose that rather than being a lost receptor, this variant may simply respond to a different, perhaps smaller, agonist that has not yet been tested. The bulkier valine residue could sterically reshape the ligand-binding pocket or restrict the conformational movements of the transmembrane helices needed for receptor activation. Similarly, for TAS2R38-AVI, the demonstration of structural integrity at the cell surface supports earlier speculation that this variant may have evolved altered ligand specificity, possibly responding to unknown compounds in the pulp of the Antidesma bunius fruit, which produces a peculiar bitter taste in individuals carrying the AVI haplotype.

The four orphan receptors yielded equally revealing results. All four could be detected at the cell surface by luminescence assays, but their trafficking efficiencies differed dramatically. TAS2R19 stood out as the star performer: 83 percent of its total receptor pool reached the plasma membrane, a proportion exceeding even that of TAS2R14, the human bitter receptor with the largest number of known agonists. TAS2R60 was by far the most abundantly produced receptor subtype, and although only 9 percent of it reached the surface, the absolute quantity there surpassed all TAS2Rs except TAS2R19. In sharp contrast, TAS2R42 and TAS2R45 showed negligible surface signals in immunocytochemical staining, with cell surface fractions of just 3 and 6 percent respectively. TAS2R42 is synthesized reasonably well but trafficked poorly, suggesting retention in the endoplasmic reticulum, while TAS2R45 appears to be produced at very low levels overall, raising the possibility that it may functionally represent an expressed pseudogene.

The contrasting profiles of the four orphans allow the authors to draw nuanced conclusions about why these receptors have resisted de-orphanization. For TAS2R19 and TAS2R60, biosynthesis and cell surface routing in heterologous cells clearly do not explain the absence of known agonists. Both receptors are closely related to already de-orphaned receptors in mice: the mouse receptor Tas2r135, an ortholog of TAS2R60, has 11 identified bitter agonists, and TAS2R19 is highly homologous to TAS2R20, which has 10 known agonists. Problems with coupling to the calcium signaling cascade used in the assay system also seem unlikely, given that far more distantly related receptors, including one from cartilaginous fish, have been successfully screened in the same cellular platform. The most probable explanation for these two receptors is simply that the right bitter compounds have not yet been tested, pointing toward unexplored chemical territory.

That territory, the authors argue, is vast and seriously under-sampled. Most bitter agonist discovery has focused on synthetic compounds and molecules from flowering plants, while bitter substances from animals, mushrooms and other fungi, prokaryotic organisms, and plants belonging to older lineages of the plant kingdom have barely been investigated. Recent work identifying bitter compounds from mushrooms, such as those isolated from the bracket fungus Amaropostia stiptica, illustrates the kind of neglected sources that could harbor activators for the remaining orphans. Closing this knowledge gap, the study suggests, will require intensified bioprospecting efforts guided by the growing recognition that bitter taste receptors do far more than guard the tongue. They are expressed in the gut, airways, and other tissues, where they influence hormone secretion, glucose homeostasis, and possibly innate defense, making every de-orphanized receptor a potential target for nutrition and medicine.

The HiBiT-based localization assay itself may prove to be the study’s most lasting contribution. By providing a rapid, quantitative, high-throughput readout of receptor biosynthetic integrity that requires no knowledge of agonists, the method offers a rational triage tool for the bitter taste receptor field. Receptors that traffic well, like TAS2R19 and TAS2R60, become priority targets for expanded ligand screening, while those with severe trafficking defects, like TAS2R42 and TAS2R45, may need engineered chaperones, modified expression systems, or tissue-specific organoid models to reveal their secrets. As the authors note, genetically engineered organoids derived from taste tissue or the intestine could eventually provide more natural cellular environments for such studies, overcoming limitations of immortalized cell lines that express numerous receptors endogenously. For now, the message is clear: four orphan receptors and two supposedly dead receptor variants are very much alive at the cell surface, waiting for the right molecule to wake them.

Subject of Research: Cell surface localization of orphan and nonfunctional human bitter taste receptors

Article Title: Cell surface localization of receptors considered nonfunctional and orphan bitter taste receptors

Article References: Kumar, P., & Behrens, M. (2026). Cell surface localization of receptors considered nonfunctional and orphan bitter taste receptors. Current Research in Food Science, 13, Article 101551. https://doi.org/10.1016/j.crfs.2026.101551

Image Credits: AI Generated

DOI: 10.1016/j.crfs.2026.101551

Keywords: bitter taste receptors, TAS2R, orphan receptors, HiBiT tag, cell surface localization, G protein-coupled receptors, TAS2R38, TAS2R9, de-orphanization, taste perception, receptor trafficking, food science

Bitter taste receptors, belonging to the T2R family, have traditionally been studied within the context of oral sensory perception. However, emerging evidence has shown that these receptors are not confined to the oral cavity but are also expressed in the gastrointestinal tract, especially within neuropod cells involved in signaling between the gut and brain. This expanded understanding necessitates a detailed comprehension of their molecular structures to elucidate their diverse physiological functions, ranging from nutrient sensing to modulating appetite and glucose metabolism.

The current landscape of bitter taste receptor structural biology has been limited by the complexities intrinsic to membrane-bound G protein-coupled receptors (GPCRs) like T2Rs, whose hydrophobic regions and conformational flexibility pose significant challenges for experimental determination. Until now, only two human T2R structures, T2R14 and T2R46, had been resolved through experimental techniques such as cryo-electron microscopy (cryo-EM). To overcome these limitations, the research team harnessed the cutting-edge capabilities of AF3, an artificial intelligence model that marks an advancement over its predecessor, AlphaFold2 (AF2), in precision and reliability of protein structure predictions.

The researchers systematically retrieved amino acid sequences for all 25 identified human T2Rs from the UniProt database and applied the AF3 algorithm to predict their three-dimensional conformations. These in silico models were rigorously compared to the previous AF2 predictions and validated against available experimental data from the Protein Data Bank. The AF3 model demonstrated superior accuracy, particularly in reproducing the structural nuances of T2R14 and T2R46, as benchmarked against a comprehensive set of 115 cryo-EM structures for T2R14, emphasizing its potential to revolutionize receptor biology disciplines.

The structural analyses revealed both conserved and divergent elements within the T2R family. The intracellular domains, which interface with signal transduction machinery such as G proteins, exhibited notable structural conservation across different T2Rs, suggesting a preserved mechanism of intracellular signaling. Conversely, extracellular domains, responsible for ligand recognition, displayed considerable structural heterogeneity, underpinning the wide range of bitter compounds these receptors can detect. This dichotomy in structural conservation has important implications for understanding receptor specificity and function.

Based on structural similarities determined via sophisticated clustering algorithms, the T2Rs were segregated into three distinct clusters. Such clustering is valuable for decoding functional relationships among receptors and predicting ligand-receptor interactions, providing a roadmap for future pharmacological targeting. This categorization elucidates the evolutionary adaptations that have diversified bitter taste sensing, likely reflecting the need to detect an extensive array of potentially harmful bitter molecules in the environment.

Central to the bitter taste signaling pathway is the G protein α-gustducin, which couples with bitter taste receptors upon ligand binding to initiate intracellular signaling cascades. The structural predictions indicate that the varied extracellular pockets accommodate binding of structurally diverse bitter ligands, which in turn activate α-gustducin to mediate downstream physiological responses. These molecular interactions underline the intricate biochemical dialogue that enables bitter taste perception and its ancillary roles in gut-brain communication.

The implications of this study extend far beyond sensory biology. The expression of T2Rs in gastrointestinal tissues implicates them in fundamental processes such as glucose homeostasis and appetite regulation, highlighting their emerging relevance in metabolic disorders like diabetes. Understanding the structural basis of T2R activation could facilitate the design of therapeutic agents aimed at modulating these receptors to treat or prevent lifestyle-related diseases.

Moreover, by leveraging AF3’s enhanced predictive power, this research exemplifies the transformative impact of artificial intelligence on structural biology, offering a route to decipher protein conformations that are difficult to resolve experimentally. AF3’s ability to generate high-fidelity models enables scientists to explore receptor-ligand interactions at an atomic level, accelerating drug discovery and the development of novel nutraceuticals targeting taste receptors.

Professor Osakabe emphasizes the significance of these findings in bridging molecular structure with physiological function, underscoring the importance of continued research to unravel how individual variations in T2R sequences and structures contribute to differences in bitter taste perception among individuals. Such personalized insights could inform dietary recommendations and therapeutic interventions tailored to individual sensory profiles.

The study, published on July 22, 2025, in the journal Current Research in Food Science, represents a collaborative effort involving experts in computational modeling and receptor biology, marking a milestone in taste receptor research. It propels the scientific community toward a more comprehensive understanding of how bitter taste receptors operate within and beyond the sensory realm, revealing their vital roles in human health and disease.

Looking ahead, the integration of AI-driven structural predictions with functional assays promises to uncover the full spectrum of T2R-mediated physiological effects, including their influence on gut microbiota, immune responses, and central nervous system signaling. This integrative approach will not only shed light on the molecular underpinnings of taste but also pave the way for innovative strategies to modulate taste receptors for health benefits.

In conclusion, the deployment of AlphaFold3 by Prof. Osakabe and her team has inaugurated a new era of receptor structural characterization. By illuminating the three-dimensional landscape of human bitter taste receptors with unprecedented detail, this study enriches our molecular understanding and underscores the potential of AI-driven approaches to transform biomedical research.

Subject of Research: Computational simulation/modeling of bitter taste receptor protein structures using AlphaFold3.

Article Title: The three-dimensional structure prediction of human bitter taste receptor using the method of AlphaFold3

News Publication Date: 22-Jul-2025

Web References:

• Current Research in Food Science article
• DOI: 10.1016/j.crfs.2025.101146

References:
Osakabe, N., Shimizu, T., Ohno, R., Calabrese, V. (2025). The three-dimensional structure prediction of human bitter taste receptor using the method of AlphaFold3. Current Research in Food Science, Volume 11.

Image Credits: Professor Naomi Osakabe, Shibaura Institute of Technology, Japan